Q2 EPS Forecast for Halozyme Therapeutics Lowered by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Stock analysts at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a research note issued on Wednesday, February 5th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of $1.06 for the quarter, down from their previous forecast of $1.07. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.87 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q3 2025 earnings at $1.14 EPS and Q4 2026 earnings at $1.78 EPS.

Several other research firms also recently issued reports on HALO. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday. JMP Securities lifted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company lowered their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Stock Performance

HALO opened at $57.94 on Friday. The business’s 50-day moving average price is $51.18 and its two-hundred day moving average price is $54.38. Halozyme Therapeutics has a 1 year low of $34.36 and a 1 year high of $65.53. The company has a market capitalization of $7.37 billion, a price-to-earnings ratio of 19.19, a P/E/G ratio of 0.43 and a beta of 1.25. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in shares of Halozyme Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after acquiring an additional 30,901 shares during the last quarter. Congress Asset Management Co. raised its position in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Halozyme Therapeutics by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock worth $85,254,000 after purchasing an additional 9,780 shares during the last quarter. Boston Trust Walden Corp raised its position in Halozyme Therapeutics by 28.0% during the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock worth $41,790,000 after purchasing an additional 191,465 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in Halozyme Therapeutics by 60.0% during the 4th quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company’s stock worth $31,112,000 after purchasing an additional 243,940 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.70% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.